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Age and Clinical 
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The relationship between age and risk for classic den-
gue fever has never been quantiﬁ  ed. We use data from clin-
ical patients to show that the relative risk of having classical 
disease after primary dengue virus infection increases with 
age. This relationship has implications for strategies aimed 
at controlling dengue fever.  
D
engue fever has emerged as a serious international 
public health threat with almost half of the world’s 
population at risk for infection (1). Although >50 million 
cases of dengue fever are estimated to occur each year (2), 
a large proportion of infections are asymptomatic (3).Why 
infection progresses to clinical disease in some persons, but 
not in others, is not clear. Some evidence suggests that risk 
for disease, with both classic dengue fever and the more se-
vere dengue hemorrhagic fever, varies by age (4); however, 
the relationships have never been rigorously quantiﬁ  ed. We 
used data from patients with laboratory-conﬁ  rmed clinical 
dengue to describe the relationship between age and the 
relative risk of becoming ill with classical disease after pri-
mary infection with dengue virus. A clearer understanding 
of this relationship has implications for strategies aimed at 
controlling dengue fever.
The Study
Clinical dengue incidence data that have been serolog-
ically conﬁ  rmed were abstracted from a survey conducted 
in 1997 in the communities of Belém and Ananindeua in 
Pará State, Brazil (5). In 1996, these communities reported 
their ﬁ  rst cases of dengue fever (dengue serotype l) in >50 
years, after the successful control of Aedes aegypti mos-
quitoes during the 1940s (5). We assumed, therefore, that 
persons <50 years of age were susceptible to all 4 dengue 
serotypes at the time of the survey and, as a result, that most 
reported cases were due to primary dengue infection. Age-
stratiﬁ  ed population data from the 2000 Brazilian census 
were used to estimate the total population of Belém and 
Ananindeua for the following age classes: 0–4, 5–9, 10–14, 
15–24, 25–34, 35–44, and 45–54 years. The midpoints of 
these age classes were used in subsequent statistical anal-
yses. Survey data describing the number of serologically 
conﬁ  rmed clinical dengue cases were then used to estimate 
the minimum proportion of all persons in each age class 
who had clinical dengue (Figure, Panel A). 
We further investigated the relationship between age 
and probability of having clinical disease by calculating 
the risk for each age class relative to the age class that had 
the highest proportion of clinical cases. Unlike the absolute 
proportion, the relative risk is independent of transmission 
intensity. In calculating relative risk, we assumed that the 
risk for dengue infection was independent of age, which 
was corroborated by a seroepidemiologic study performed 
in Fortaleza, Brazil, in 1994 (6). A logistic regression mod-
el was developed to describe the relationship between age 
and the relative probability of disease after primary dengue 
infection. Model ﬁ  tting was performed with Stata 8.0 (Stata 
Corporation, College Station, TX, USA), and robust stan-
dard errors were calculated for each regression coefﬁ  cient.
The logistic model provided a signiﬁ  cant ﬁ  t to the 
data (McFadden R2 = 0.512, χ2 = 4.86, df = 1, p<0.028) 
and described a clear positive relationship between age 
and relative risk for clinical disease (β = 0.164; bootstrap 
Figure. Estimated minimum proportion of the population, by age, 
with laboratory-conﬁ   rmed classical dengue, showing exact 95% 
binomial conﬁ  dence intervals. A) Fitting a logistic regression model 
(not shown) to the absolute proportion produced a signiﬁ  cant age 
estimate: McFadden R2 = 0.762, χ2 = 5,196.13, df = 1, p<0.001. 
B) Relative risk, by age, of having classical dengue after primary 
infection. Black circles, observed; line, model ﬁ  t. See text for details 
of statistical analysis.
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95% conﬁ  dence interval 0.1470–0.1769), as shown in the 
Figure, Panel B. The results suggest that the risk for clini-
cal disease after primary dengue infection is relatively low 
throughout childhood and then increases rapidly through 
adolescence and early adulthood.
Conclusions
To our knowledge, this is the ﬁ  rst time data have 
been used to empirically derive the quantitative relation-
ship between age at time of primary dengue infection and 
risk of having clinical dengue fever. These ﬁ  ndings are 
consistent with results of earlier studies that suggest that 
adults are more likely than young children to have clinical 
dengue (7–9). 
Several factors should be considered when interpreting 
these results. First, because dengue virus serotypes l and 2 
were circulating in the population during the study period, 
some persons may have been infected with both serotypes 
during the 1-year period and, therefore, clinical signs may 
have resulted from a secondary infection. This proportion 
is probably small. Second, several factors other than age 
are thought to inﬂ  uence severity of classic dengue illness, 
including viral serotype and strain (4,10). Data from a den-
gue epidemic (dengue virus type 3) in Puerto Rico showed 
the attack rate to be independent of age (11). Although the 
proportion of these cases that were due to primary infec-
tion was uncertain, the different infecting serotype may be 
partly responsible for the conﬂ  icting ﬁ  ndings between that 
study and ours. Further research should be conducted to 
determine whether the relationship between age and classic 
dengue fever is similar in epidemics involving all 4 dengue 
virus serotypes. Finally, whether all age groups in the study 
population had equal access to participating health facilities 
is not known. However, if a reporting bias were introduced, 
it would likely be in adults (because of child-rearing duties 
and difﬁ  culty taking time off work). Therefore, because 
adults represent a higher proportion of total patients with 
clinical cases in this study, underreporting in this age group 
would suggest that our relative-risk estimates in the adult 
age classes are conservative.
Despite the complexities of dengue epidemiology, 
these ﬁ  ndings provide strong empirical evidence that age 
is an important factor in determining risk for disease se-
verity after primary dengue virus infection. As such, these 
ﬁ  ndings have important implications for initiatives aimed 
at controlling dengue. Interventions focused on reducing 
the number of Aedes mosquitoes are the mainstay of den-
gue control worldwide. Such approaches, however, have 
proved incapable of interrupting dengue transmission (12). 
At best, vector control may result in a partial reduction in 
the rate at which dengue virus is transmitted, which conse-
quently increases the average age of the population suscep-
tible to dengue infection. If age is a risk factor for clinical 
dengue fever, as our results suggest, then while partial con-
trol will decrease the rate of dengue infection, it may have 
the adverse effect of increasing clinical incidence.
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